vs
Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and Lifeway Foods, Inc. (LWAY). Click either name above to swap in a different company.
Lifeway Foods, Inc. is the larger business by last-quarter revenue ($55.4M vs $37.2M, roughly 1.5× GYRE THERAPEUTICS, INC.). Lifeway Foods, Inc. runs the higher net margin — 4.6% vs -3.7%, a 8.3% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 18.0%). GYRE THERAPEUTICS, INC. produced more free cash flow last quarter ($-5.8M vs $-17.4M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs 11.4%).
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
Lifeway Foods is an Illinois-based health food company founded in 1986. They are a leading U.S. supplier of kefir and fermented probiotic products to support the microbiome.
GYRE vs LWAY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $37.2M | $55.4M |
| Net Profit | $-1.4M | $2.5M |
| Gross Margin | 95.3% | 27.8% |
| Operating Margin | 0.3% | 6.8% |
| Net Margin | -3.7% | 4.6% |
| Revenue YoY | 33.4% | 18.0% |
| Net Profit YoY | -340.1% | 1688.1% |
| EPS (diluted) | $-0.01 | $0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $37.2M | $55.4M | ||
| Q3 25 | $30.6M | $57.1M | ||
| Q2 25 | $26.8M | $53.9M | ||
| Q1 25 | $22.1M | $46.1M | ||
| Q4 24 | $27.9M | $46.9M | ||
| Q3 24 | $25.5M | $46.1M | ||
| Q2 24 | $25.2M | $49.2M | ||
| Q1 24 | $27.2M | $44.6M |
| Q4 25 | $-1.4M | $2.5M | ||
| Q3 25 | $5.9M | $3.5M | ||
| Q2 25 | $1.6M | $4.2M | ||
| Q1 25 | $3.7M | $3.5M | ||
| Q4 24 | $569.0K | $-160.0K | ||
| Q3 24 | $2.9M | $3.0M | ||
| Q2 24 | $4.5M | $3.8M | ||
| Q1 24 | $9.9M | $2.4M |
| Q4 25 | 95.3% | 27.8% | ||
| Q3 25 | 94.7% | 28.7% | ||
| Q2 25 | 95.7% | 28.6% | ||
| Q1 25 | 95.9% | 23.9% | ||
| Q4 24 | 95.8% | 25.3% | ||
| Q3 24 | 96.2% | 25.7% | ||
| Q2 24 | 96.9% | 27.0% | ||
| Q1 24 | 96.4% | 25.8% |
| Q4 25 | 0.3% | 6.8% | ||
| Q3 25 | 22.7% | 8.8% | ||
| Q2 25 | 8.1% | 10.8% | ||
| Q1 25 | 10.3% | 3.4% | ||
| Q4 24 | 2.4% | 1.5% | ||
| Q3 24 | 16.6% | 9.1% | ||
| Q2 24 | 12.7% | 11.0% | ||
| Q1 24 | 29.7% | 8.0% |
| Q4 25 | -3.7% | 4.6% | ||
| Q3 25 | 19.4% | 6.2% | ||
| Q2 25 | 5.9% | 7.9% | ||
| Q1 25 | 16.9% | 7.7% | ||
| Q4 24 | 2.0% | -0.3% | ||
| Q3 24 | 11.2% | 6.5% | ||
| Q2 24 | 18.0% | 7.7% | ||
| Q1 24 | 36.6% | 5.4% |
| Q4 25 | $-0.01 | $0.15 | ||
| Q3 25 | $0.03 | $0.23 | ||
| Q2 25 | $0.00 | $0.28 | ||
| Q1 25 | $0.00 | $0.23 | ||
| Q4 24 | $0.00 | $0.00 | ||
| Q3 24 | $0.01 | $0.19 | ||
| Q2 24 | $0.01 | $0.25 | ||
| Q1 24 | $0.03 | $0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.4M | $5.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $106.0M | $85.8M |
| Total Assets | $166.1M | $105.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.4M | $5.6M | ||
| Q3 25 | $60.0M | $23.0M | ||
| Q2 25 | $54.4M | $21.2M | ||
| Q1 25 | $29.9M | $19.4M | ||
| Q4 24 | $26.7M | $16.7M | ||
| Q3 24 | $25.1M | $20.6M | ||
| Q2 24 | $25.1M | $14.6M | ||
| Q1 24 | $37.4M | $12.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $2.5M |
| Q4 25 | $106.0M | $85.8M | ||
| Q3 25 | $101.9M | $82.8M | ||
| Q2 25 | $92.0M | $78.7M | ||
| Q1 25 | $68.1M | $74.2M | ||
| Q4 24 | $63.3M | $71.9M | ||
| Q3 24 | $63.2M | $71.5M | ||
| Q2 24 | $60.4M | $68.0M | ||
| Q1 24 | $56.6M | $63.5M |
| Q4 25 | $166.1M | $105.6M | ||
| Q3 25 | $159.4M | $109.5M | ||
| Q2 25 | $152.6M | $98.3M | ||
| Q1 25 | $129.8M | $93.7M | ||
| Q4 24 | $125.4M | $90.5M | ||
| Q3 24 | $125.2M | $91.3M | ||
| Q2 24 | $120.9M | $84.9M | ||
| Q1 24 | $122.0M | $82.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.04× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.6M | $267.0K |
| Free Cash FlowOCF − Capex | $-5.8M | $-17.4M |
| FCF MarginFCF / Revenue | -15.5% | -31.5% |
| Capex IntensityCapex / Revenue | 0.4% | 31.9% |
| Cash ConversionOCF / Net Profit | — | 0.11× |
| TTM Free Cash FlowTrailing 4 quarters | $-180.0K | $-16.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.6M | $267.0K | ||
| Q3 25 | $4.7M | $6.9M | ||
| Q2 25 | $2.1M | $3.9M | ||
| Q1 25 | $-129.0K | $-150.0K | ||
| Q4 24 | $-2.8M | $-2.6M | ||
| Q3 24 | $1.7M | $7.5M | ||
| Q2 24 | $-5.5M | $6.5M | ||
| Q1 24 | $2.9M | $1.5M |
| Q4 25 | $-5.8M | $-17.4M | ||
| Q3 25 | $4.0M | $1.8M | ||
| Q2 25 | $1.8M | $1.6M | ||
| Q1 25 | $-251.0K | $-2.4M | ||
| Q4 24 | $-2.8M | $-3.8M | ||
| Q3 24 | $1.0M | $5.9M | ||
| Q2 24 | $-6.9M | $5.1M | ||
| Q1 24 | $2.7M | $-923.0K |
| Q4 25 | -15.5% | -31.5% | ||
| Q3 25 | 13.1% | 3.1% | ||
| Q2 25 | 6.8% | 3.0% | ||
| Q1 25 | -1.1% | -5.1% | ||
| Q4 24 | -10.1% | -8.2% | ||
| Q3 24 | 4.1% | 12.8% | ||
| Q2 24 | -27.5% | 10.4% | ||
| Q1 24 | 9.8% | -2.1% |
| Q4 25 | 0.4% | 31.9% | ||
| Q3 25 | 2.2% | 9.0% | ||
| Q2 25 | 1.0% | 4.3% | ||
| Q1 25 | 0.6% | 4.8% | ||
| Q4 24 | 0.2% | 2.7% | ||
| Q3 24 | 2.7% | 3.3% | ||
| Q2 24 | 5.8% | 2.9% | ||
| Q1 24 | 0.9% | 5.5% |
| Q4 25 | — | 0.11× | ||
| Q3 25 | 0.79× | 1.96× | ||
| Q2 25 | 1.32× | 0.92× | ||
| Q1 25 | -0.03× | -0.04× | ||
| Q4 24 | -4.85× | — | ||
| Q3 24 | 0.60× | 2.50× | ||
| Q2 24 | -1.21× | 1.73× | ||
| Q1 24 | 0.29× | 0.64× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GYRE
Segment breakdown not available.
LWAY
| Drinkable Kefirotherthan Pro Bugs | $47.8M | 86% |
| Cheese | $4.7M | 8% |
| Cream And Other | $1.7M | 3% |
| Other | $1.2M | 2% |
